Pharmacology of CNS stimulants

Narcolepsy and Hypersomnia

Volumn , Issue , 2006, Pages 513-530

  Nishino, Seiji ^a   Mignot, Emmanuel ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85056684613     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (44)

1. Hartmann A, Cravens J. Sleep: effect of d-and l-amphetamine in man and rat. Psychopharmacology 1976; 50:171-175.
2. Kuczenski R, Segal DS. Neurochemistry of amphetamine. In: Cho AK, Segel DS, eds. Psychopharmacology, toxicology and abuse. San Diego: Acdemic Press, 1994:81-113.
3. Nishino S, Mignot E. Pharmacological aspects of human and canine narcolepsy. Prog Neurobiol 1997; 52:27-78.
4. Nishino S, Mao J, Sampathkumaran R, et al. Increased dopaminergic transmission mediates the wakepromoting effects of CNS stimulants. Sleep Research Online 1998; 1:49-61. http://www.sro.org/1998/Nishino/49/.
5. Kanbayashi T, Nishino S, Honda K, et al. Differential effects of D-and L-amphetamine isomers on dopaminergic trasmission: Implication for the control of alertness in canine narcolepsy. Sleep Res 1997; 26:383.
6. Kuczenski R, Segal DS, Cho A, et al. Hippocampus norepinephrine, caudate dopamine and serotonin and behavioral responses to the stereoisomers of amphetamine and methamphetamine. J Neurosci 1995; 15:1308-1317.
7. Wisor JP, Nishino S, Sora I, et al. Dopaminergic role in stimulant-induced wakefulness. J Neurosci 2001; 21:1787-1794.
8. Xu F, Gainetdinov RR, Wetsel WC, et al. Mice lacking the norepinephrine transporter are supersensitive to psychostimulants. Nat Neurosci 2000; 3:465-471.
9. Takahashi N, Miner LL, Sora I, et al. VMAT2 knockout mice: heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity. Proc Natl Acad Sci U S A 1997; 94:9938-9943.
10. Björklund A, Lindvall O. Dopamine-containing systems in the CNS. In: Björklund A, Hökfelt T, eds. Handbook of Chemical Neuroanatomy, Vol 2, Classical Transmitter in the CNS, Part I. Amsterdam: Elsevier, 1984:55-121.
11. Honda K, Riehl J, Mignot E, et al. Dopamine D3 agonists into the substantia nigra aggravate cataplexy but do not modify sleep. NeuroReport 1999; 10:3717-3724.
12. Cooper TB, Simpson GM. Concomitant imipramine and methylphenidate administration: a case report. Am. J. Psychiatry 1973; 130:6.
13. Zarcone V. Narcolepsy: A review of the syndrome. N Engl J Med 1973; 288:1156-1165.
14. Bastuji H, Jouvet M. Successful treatment of idiopathic hypersomnia and narcolepsy with modafinil. Prog. Neuropsychopharmacol. Biol. Psychiat. 1988; 12:695-700.
15. Billiard M, Besset A, Montplaisir J, et al. Modafinil: A double-bling multicentric study. Sleep 1994; 17:S107-S112.
16. Shelton J, Nishino S, Vaught J, et al. Comparative effects of modafinil and amphetamine on daytime sleepiness and cataplexy of narcoleptic dogs. Sleep 1995; 18:817-826.
17. Fry J, group TMs. A new alternative in the pharmacologic management of somnolence: A phase III study of modafinil in narcolepsy, Am Neurol Assoc, Miami, FL, 1996.
18. Edgar DM, Seidel WF, Contreras P, et al. Modafinil promotes EEG wake without intensifying motor activity in the rat. Canadian Journal Physiology and Pharmacology 1994; 72, S1:362.
19. Duteil J, Rambert FA, Pessonnier J, et al. Central a1-adrenergic stimulation in relation to the behaviour stimulating effect of modafinil: studies with experimental animals. Eur J Pharmacol 1990; 180:49-58.
20. Lin JS, Roussel B, Akaoka H, et al. Role of catecholamines in modafinil and amphetamine induced wakefulness, a comparative pharmacological study. Brain Res 1992; 591:319-326.
21. Tanganelli S, Fuxe K, Ferraro L, et al. Inhibitory effects of the psychoactive drug modafinil on gammaaminobutyric acid outflow from the cerebral cortex of the awake freely moving guinea pig. Arch Pharmacol 1992; 345:461-465.
22. Ferraro L, Tananelli S, O’Connor WT, et al. The vigilance promoting drug modafinil increases dopamine release in the rat nucleus accumbens via the involvement of a local GABAergic mechanism. Eur J Pharmacol 1996; 306:33-39.
23. Lin JS, Hou Y, Jouvet M. Potential brain neuronal targets for amphetamine-, methylphenidate-, and modafinil-induced wakefulness, evidenced by c-fos immunocytochemistry in the cats. Proc Natl Acad Sci USA 1996; 93:14128-14133.
24. Chemelli RM, Willie JT, Sinton CM, et al. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 1999; 98:437-451.
25. Scammell TE, Estabrooke IV, McCarthy MT, et al. Hypothalamic arousal regions are activated during modafinil-induced wakefulness. J Neurosci 2000; 20:8620-8628.
26. Gallopin T, Luppi PH, Rambert FA, et al. Effect of the wake-promoting agentmodafinil on sleep-promoting neurons from the ventrolateral preoptic nuclueus: an In vitro phramacologic study. Sleep 2004; 27:19-25.
27. Iijima S, Sugita Y, Teshima Y, et al. Therapeutic effects ofmazindol on narcolepsy. Sleep 1986; 9:265-268.
28. Nishino S, Mao J, Sampathkumaran R, et al. Adrenergic, but not dopaminergic, uptake inhibition reduces REM sleep and cataplexy concomitantly. Sleep Res 1997; 26:445.
29. Rye DB, Dihenia B, Bliwise DL. Reversal of atypical depression, sleepiness, and REM-sleep propensity in narcolepsy with bupropion. Depress Anxiety 1998; 7:92-95.
30. Hublin C, Partinen M, Heinonen EH, et al. Selegiline in the treatment of narcolepsy. Neurology 1994; 44:2095-2101.
31. Nishino S, Arrigoni J, Kanbayashi T, et al. Comparative effects of MAO-A and MAO-B selective inhibitors on canine cataplexy. Sleep Res 1996; 25:315.
32. Roselaar SE, Langdon N, Lock CB, et al. Selegiline in narcolepsy. Sleep 1987; 10:491-495.
33. Rall TR. Central nervous system stimulants. In: Gilman AG, Goodman LS, Rall TW, et al., eds. The Pharmacological Basis of Therapeutics, 7th Ed. New York: Pergamon Press, 1985:345-382.
34. Radulovacki M, Virus RM, Djuricic-Nedelson M, et al. Adenosine analogs and sleep in rats. J Pharmacol Exp Ther 1984; 228:268-274.
35. Porkka-Heiskanen T, Strecker RE, Thakkar M, et al. Adenosine: a mediator of the sleep-inducing effects of prolonged wakefulness. Science 1997; 276:1265-1268.
36. Willie JT, Chemelli RM, Sinton CM, et al. To eat or to sleep? Orexin in the regulation of feeding and wakefulness. Annu Rev Neurosci 2001; 24:429-458.
37. Fujiki N, Ripley B, Yoshida Y, et al. Effects of IV and ICV hypocretin-1 (orexin A) in hypocretin receptor-2 gene mutated narcoleptic dogs and IV hypocretin-1 replacement therapy in a hypocretin ligand deficient narcoleptic dog. Sleep 2003; 6:953-959.
38. John J, Wu MF, Siegel JM. Systemic administration of hypocretin-1 reduces cataplexy and normalizes sleep and waking durations in narcoleptic dogs. Sleep Research Online 2000; 3:23-28.
39. Mieda M, Willie JT, Hara J, et al. Orexin peptides prevent cataplexy and improve wakefulness in an orexin neuron-ablated model of narcolepsy in mice. Proc Natl Acad Sci U S A 2004.
40. Huang ZL, Qu WM, Li WD, et al. Arousal effect of orexin A depends on activation of the histaminergic system. Proc Natl Acad Sci U S A 2001; 98:9965-9970.
41. Nishino S, Fujiki N, Ripley B, et al. Decreased brain histamine contents in hypocretin/orexin receptor-2 mutated narcoleptic dogs. Neurosci Lett 2001; 313:125-128.
42. Nishino S, Sakurai E, Nevisimalova S, et al. CSF histamine content is decreased in hypocretin-deficient human narcolepsy. Sleep 2002; 25 (suppl):A476.
43. Lin JS, Sakai K, Vanni-Mercier G, et al. Involvement of histaminergic neurons in arousal mechanisms demonstrated with H3-receptor ligands in the cat. Brain Res 1990; 523:325-330.
44. Shiba T, Fujiki N, Wisor J, et al. Wake promoting effects of thioperamide, a histamine H3 antagonist in orexin/ataxin-3 narcoleptic mice. Sleep 2004; (suppl):A241-A242.